Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response correctly states that LIPITOR may be taken at any time of day with or without food and appropriately discusses the label's caution regarding substantial alcohol consumption. However, several alcohol-use limits, timing assurances, symptom lists, and recommendations are not stated in the supplied label. It also omits the label's liver-function monitoring recommendations and the contraindication for active liver disease or unexplained persistent transaminase elevations.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can be taken at any time of day, with or without food.
Section 2.1 states that LIPITOR can be administered as a single dose at any time of day, with or without food.
Alcohol can be associated with liver concerns while taking a statin, particularly with substantial alcohol consumption.
Section 5.2 describes liver-function abnormalities associated with statins and advises caution in patients who consume substantial quantities of alcohol.
Jaundice may indicate a liver problem while taking a statin.
Section 5.2 reports jaundice in a clinical-trial patient and discusses liver-function abnormalities.
Unsupported Statements
There isn’t a required time interval between Lipitor (atorvastatin) and wine.
The supplied label does not address timing or required intervals between LIPITOR and wine or alcohol.
Wine can be consumed in moderation while taking Lipitor (atorvastatin).
The label advises caution with substantial alcohol consumption but does not endorse moderate wine consumption or define a safe amount.
Moderate drinking is defined as up to 1 drink per day for women and up to 2 drinks per day for men.
The supplied label does not define moderate drinking or specify drink limits by sex.
A standard drink is about 5 ounces of wine containing roughly 12% alcohol.
The supplied label does not define a standard drink or provide serving-size or alcohol-concentration information.
Alcohol can increase the risk of liver problems with statins.
The label advises caution with substantial alcohol consumption but does not explicitly state this generalized causal relationship for all alcohol intake or all statins.
People with liver disease or elevated liver tests should avoid or limit alcohol while taking statins and follow their clinician’s advice.
The label advises caution in patients with a history of liver disease or substantial alcohol consumption, but it does not provide this specific alcohol-avoidance instruction or wording.
Binge drinking should be avoided while taking statins.
The label does not mention binge drinking or specifically instruct patients to avoid it.
Dark urine, severe fatigue, or right upper abdominal pain may indicate a liver problem while taking a statin.
These symptoms are not identified in the supplied label sections.
Contradictions
Important Omissions
The label identifies active liver disease or unexplained persistent transaminase elevations as contraindications to LIPITOR.
Importance:
High
The label recommends liver-function tests before treatment, at 12 weeks after initiation and after each dose increase, and periodically thereafter.
Importance:
High
The label recommends monitoring patients with increased transaminase levels and reducing the dose or withdrawing LIPITOR if ALT or AST elevations greater than three times the ULN persist.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response does not directly contradict the supplied label, but its statement that moderate wine consumption is permissible and its specific drinking limits could be interpreted as label-endorsed safety thresholds. It also omits the liver contraindication and label-directed liver-function monitoring, while presenting several symptoms not listed in the supplied label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The response adds non-label alcohol definitions and permissions and omits important liver contraindication and monitoring information.
Suggested Improvement
Restrict the alcohol discussion to the label's statement that LIPITOR should be used with caution in patients consuming substantial quantities of alcohol or with a history of liver disease. Explicitly state that active liver disease or unexplained persistent transaminase elevations are contraindications and include the label's liver-function testing and persistent-transaminase-elevation actions.